Rare Diseases Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

This study is following people with spinal muscular atrophy (SMA) who are taking risdiplam, an oral medicine, to see how safe and effective it is over a longer time. For patients and families, this means learning more about how risdiplam might help manage SMA symptoms and improve quality of life over about two years. The research is happening at several locations across the United States and Puerto Rico, giving a broad look at this treatment’s impact.

A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

This trial is checking how safe and helpful long-term use of vamorolone is for boys with Duchenne muscular dystrophy. Vamorolone might improve muscle strength while causing fewer side effects than current treatments. The study includes boys from multiple countries who have previously taken vamorolone, offering important information on how this medicine works over time.

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia

This trial is testing a weekly injection called navepegritide in teenagers with achondroplasia, a rare condition that affects bone growth. The goal is to see if this treatment can safely help these young people grow better. The study is recruiting in Canada, Europe, and other places, and results will be available after one year of treatment, offering hope for new growth options.

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

This research is looking at the best dose and safety of a new medicine called TYRA-300 for children with achondroplasia. If it works well, it could become another choice to help improve growth in kids with this condition. The study is active in the United States, Australia, and Canada, aiming to find a safe and effective treatment for affected children.

Safety and Efficacy of PTH-IA

This trial is exploring a new drug named PTH-IA for people with Jansen’s Metaphyseal Chondrodysplasia, a very rare bone disorder. It includes both children and adults over age three. If this treatment is successful, it could be the first targeted therapy to help improve symptoms and quality of life for those living with this condition in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.